On Tuesday, Shares of Pfizer Inc. (NYSE:PFE), gained 0.62% to $31.01.
Merck and Pfizer recently declared that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer. Each year, there are about 1,500 new cases of MCC diagnosed in the US.
Avelumab (also referred to as MSB0010718C) is an investigational fully human monoclonal IgG1 antibody against programmed death-ligand 1 (anti-PD-L1). Merck and Pfizer are presently conducting a Phase II study (JAVELIN Merkel 200) to assess the safety and efficacy of avelumab in patients with metastatic MCC who have progressed after at least one prior chemotherapy regimen.
JAVELIN Merkel 200 is a multicenter, single-arm, open-label study evaluating patients with metastatic MCC who have formerly received at least one line of chemotherapy. The primary endpoint is objective response rate, and secondary endpoints comprise duration of response, progression-free survival, overall survival and safety. The study, which exceeded its predictable enrollment of 84 patients with 88 patients enrolled, is being conducted in sites across Asia Pacific, Australia, Europe and North America.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products comprise Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others.
Shares of Exxon Mobil Corporation (NYSE:XOM), inclined 0.50% to $72.96, during its last trading session.
Exxon Mobil Corporation is expanding its operations in Jurong to produce synthetic lubricants, counting Mobil 1TM, the company’s flagship synthetic engine oil. The expansion will further strengthen the company’s manufacturing capabilities and ability to meet the growing demand for ExxonMobil synthetic products in the Asia Pacific region.
When accomplished in the second half of 2017, the facility will be the only plant in the Asia Pacific producing Mobil 1, the world’s leading synthetic motor oil. The facility will be one of five locations where Mobil 1 is produced.
The lubricant plant, plannedally located next to ExxonMobil’s manufacturing site in Jurong, adds to the company’s increasing lubricants and specialties production capabilities in Singapore. The company, which has operated in Singapore for more than a century, has continued to grow its integrated refining and petrochemicals manufacturing site. The new production facility is in addition to the company’s recently declared grease manufacturing investment.
Exxon Mobil Corporation is an energy company. The Company is engaged in the exploration and production of crude oil and natural gas. The Company is involved in the manufacturing of petroleum products, and transportation and sale of crude oil, natural gas and petroleum products.
Shares of Ceres Inc (NASDAQ:CERE), inclined 27.49% to $1.28, during its last trading session.
Ceres declared that KWS SAAT SE, a global seed developer with operations in over 70 counties, will evaluate Ceres’ Persephone bioinformatics technology under a license agreement.
Originally developed for in-house use by Ceres, the Persephone system allows researchers to organize, store, access and explore a diverse array of DNA-related information in much the same way online mapping programs allow users to explore geographic regions and locations.
Swaller noted that next generation sequencing technologies have substantially raised the amount and complexity of information generated in crop research and development. Despite the power of this information, it is often difficult to access and fully utilize throughout a research organization. “Persephone’s capabilities and user experience is designed to allow more eyes on information that is often inaccessible recently,” said Swaller.
KWS, which develops, produces and markets seed for corn, sugarbeet, cereals, potatoes, canola and sunflower, has more than 1,000 employees involved in research, counting large-scale genomic research programs across its major products lines.
Ceres, Inc. (Ceres) is an agricultural biotechnology company that develops and markets seeds to produce crops for bioenergy and other markets that utilize plant biomass. It uses a combination of advanced plant breeding, biotechnology and bioinformatics to develop seed products. One of commercial opportunities is in Brazil where the Company is pursuing multiple markets for its sorghum products.
Finally, Eli Lilly and Co (NYSE:LLY), ended its last trade with 0.65% gain, and closed at $80.26.
Eli Lilly and Company and Incyte Corporation (INCY) declared positive top-line results of RA-START, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA). The study met its primary objective of demonstrating non-inferiority of baricitinib monotherapy to methotrexate monotherapy based on ACR20 response rate after 24 weeks of treatment. Additionally, baricitinib was superior to methotrexate based on ACR20 response.
The RA-START study comprised patients who had limited or no prior treatment with methotrexate, and were naïve to other conventional or biologic disease-modifying antirheumatic drugs (DMARDs). Part of a larger Phase 3 program of more than 3,000 RA patients at various points in the RA treatment continuum, RA-START enrolled nearly 600 patients who were randomized to one of the following treatment groups:
- Once-weekly oral methotrexate monotherapy
- 4 mg once-daily oral baricitinib monotherapy
- 4 mg once-daily oral baricitinib in combination with once-weekly oral methotrexate
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in about 120 countries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
